“Clinical Efficacy and Patient Reported Impacts of Roflumilast Foam 0.3% in Seborrheic Dermatitis: An Analysis of STRATUM Data for Patients Unresponsive or Intolerant to Topical Corticosteroids”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 2, Mar. 2024, p. s397, https://doi.org/10.25251/skin.8.supp.397.